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A large outbreak of vancomycin-resistant enterococci 
(VRE) is affecting four hospitals in the Canton of Bern, 
Switzerland, since December 2017. Of 89 cases identi-
fied as carriers, 77 (86.5%) VRE isolates were virtually 
indistinguishable using whole genome sequencing, 
and identified as multilocus sequence type (MLST) 
ST796. This clone, previously only described in 
Australia and New Zealand, is characterised by rapid 
spread and the ability to cause bloodstream infec-
tions. It requires a multifaceted infection prevention 
effort.
Vancomycin-resistant enterococci (VRE) are multidrug-
resistant microorganisms that cause healthcare-asso-
ciated infections and are associated with an increased 
risk of mortality and length of hospital stay [1,2]. An 
outbreak with VRE affected several hospitals in the 
Canton of Bern since December 2017, with a new 
VRE clone ST796 characterised by a rapid intra- and 
inter-hospital dissemination. This clone has recently 
emerged in Australia and New Zealand and has quickly 
spread between hospitals [3]; VRE ST796 has not yet 
been described in Europe. Here, we describe a large 
outbreak of this clone across multiple hospitals in 
Switzerland and illustrate the genetic relationship of 
the Swiss and Australian isolates.
Description of the outbreak and outbreak 
strain analysis
The data reported here were obtained from 30 December 
2017 to 30 April 2018. An outbreak investigation was 
started when two cases of VRE E. faecium bloodstream 
infection were reported on the haemato-oncology ward 
of Bern University Hospital on 30 December 2017.
Colonies from selective media identified as  E. fae-
cium with Matrix Assisted Laser Desorption/Ionisation 
Time-of-Flight (MALDI-TOF) mass spectrometry 
(Bruker Daltonics, Bremen, Germany) were screened 
(Xpert vanA/vanB, Cepheid, Sunnyvale, California 
(CA), United States (US)) for rapid detection 
of  vanA  and  vanB  resistance genes before phenotypic 
susceptibility testing by Clinical Laboratory Standards 
Institute (CLSI) disk diffusion and Etest (bioMérieux, 
Marcy l’Étoile, France). All VRE isolates were analysed 
by whole genome sequencing (WGS) to support epide-
miological linkage (Supplement 1). WGS sequencing 
was performed using a MiSeq Illumina platform (accred-
ited with ISO 17025 norm at the Division of Clinical 
Microbiology, University Hospital Basel) with 2 x 300nt 
paired-end sequencing after Nextera XT library prepa-
ration. The resulting reads were de novo assembled 
and analysed by core genome multilocus sequence typ-
ing (cgMLST) within Ridom SeqSphere Software (ver-
sion 4.1.6). Additional ST796 strain genome sequences 
were downloaded from databases for comparison [4,5]. 
All read data have been deposited with the European 
Nucleotide Archive (ENA) (https://www.ebi.ac.uk/ena) 
under the project number PRJEB27159.
Three of six hospitals within the Bern University 
Hospital group were affected (one university hospital, 
one community hospital, one rehabilitation centre), 
as well as a community hospital about 40 km away 
from Bern, in the university hospital’s catchment area 
(Figure 1).
As at April 2018, 3,096 screening samples were 
obtained from contact patients and 89 patients were 
found to be colonised or infected with VRE (Table 1). In 
these 89 patients, 77 (86.5%) of isolates were found to 
be virtually indistinguishable by cgMLST (separated by 
up to three alleles) and identified as MLST type ST796 
(Figure 2). All of these carried the resistance type vanB.
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Figure 1
Distribution of vancomycin-resistant Enterococcus faecium ST796 in four different hospitals, Canton of Bern, Switzerland, 
30 December 2017 to 30 April 2018 (n = 89)
Switzerland
Canton of Bern
The largest outbreak at University hospital is shown by the largest circle.
Table 1
Description of vancomycin-resistant Enterococcus faecium ST796 outbreak isolates in four different hospitals, Canton of 
Bern, Switzerland, 30 December 2017–30 April 2018, (n= 89)
All patients 
 
(N = 89)
VRE isolates ST796 
 
(n = 77)
Other VRE isolates STa,b 
 
(n = 15)
n % n % n %
Mean age (median) 67.9 69 68.9 71 62.1 64.5
Female 38 42.7 34 44.2 3 20
Resistance type vanB 81 91 77 100 7 46.7
University hospital 74 83.1 63 81.8 14 93.3
Haemato-oncology 28 31.5 27 35.1 2 13.3
Invasive infectionc 7 7.9 7 9.1 1 6.7
BSI 5 5.6 5 6.5 0 0
Community hospital 1 2 2.2 2 2.6 0 0
Community hospital 2 9 10.1 8 10.4 1 6.7
Rehabilitation centre 4 4.5 4 5.2 0 0
BSI: bloodstream infection; ST: sequence type; VRE: vancomycin-resistant enterococci.
a The VRE isolate was not sequenced in one patient. Four patients had dual infection.
b MLST types ST117, ST555, ST78, ST17, ST80.
c Bloodstream infections (n = 5); abdominal abscess (n = 1); deep wound infection (n = 1). All invasive isolates were detected in the university 
hospital.
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In six patients, VRE was initially detected in clinical 
samples (and not in screening samples), of whom five 
carried the outbreak strain ST796. Of 77 patients colo-
nised or infected with VRE ST796, the mean age was 
68.9 years, 34 (44%) were female, seven (7.9%) devel-
oped an invasive infection: five (6.5%) bacteraemia, 
one (1.3%) abdominal abscess and one (1.3%) deep 
wound infection. Temporo-spatial links were found 
for almost all patients in whom the outbreak strain 
was detected during the course of the outbreak (i.e. 
patients had shared a room or were treated by the 
same healthcare worker).
Of the 77 ST796 isolates, antimicrobial susceptibility 
profiles were obtained from 68 and showed resistance 
to ampicillin, levofloxacin and high-level resistance to 
gentamycin, but not streptomycin. Forty-six isolates 
were resistant to vancomycin (minimum inhibitory 
concentration (MIC)  >  16mg/L), 21 were intermediate 
(MIC 8–16mg/L) and one tested susceptible (4mg/L) 
(median MIC 32 mg/L). All isolates were susceptible to 
teicoplanin (median MIC 0.5mg/L). The remaining iso-
lates were identified as MLST type ST117 (n = 6), ST555 
(n  =  2), ST78 (n  =  4), ST17 (n  =  1) and ST80 (n  =  1). 
Only eight isolates detected during this period car-
ried vanA (Figure 2).
The genomes of the Swiss outbreak isolates (ST796) 
all map to >  97% of the reference genome Ef_aus0233 
from Australia, separated by ca 27 single nucleotide 
Figure 2
Core genome multilocus sequencing typing multiple spanning tree of Enterococcus faecium isolates, the Canton of Bern 
outbreak, Switzerland and isolates detected in Australia, 30 December 2017–30 April 2018
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The core genome multi locus sequencing typing (cgMLST) analysis is based on 1423 loci [14] and was performed in Ridom Seqsphere v4.1.6.
Number of isolates belonging to each cluster is shown in the circles and the number of allele differences between clusters is presented on 
the connecting lines. Outbreak strains are shown in dark blue*, with the clonal complex highlighted in grey. Reference ST796 strains from 
Australia are shown in pink.
a Isolates carrying vanA.
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polymorphisms (SNPs), some of which cluster, indica-
tive of recombination (Supplement 2 and Figure 2).
The outbreak management strategy
After the outbreak was declared on 4 January 2018, a 
VRE outbreak team was formed. A large outbreak inves-
tigation and management strategy was started immedi-
ately, including temporary admission stops in affected 
wards. Patients colonised or infected with VRE were 
cohorted and placed under contact precautions; staff 
cohorting was also implemented. Contact patients of 
VRE positive patients were retrospectively identified, 
screened on a weekly basis (3 negative screenings (0, 
7, 14 days if hospitalised) and pre-emptively placed 
under contact precautions or if already discharged 
tagged in an electronic alarm system. Environmental 
disinfectant cleaning was implemented and intensified 
where VRE transmissions had been identified. Wards 
that had housed patients colonised with VRE were sub-
ject to cross-sectional screening. Hand hygiene compli-
ance was reinforced on every occasion.
With these measures in place, an initial decrease 
in new detections of VRE cases during the follow-
up period was observed (January 2018–April 2018). 
The epidemiologic curve of VRE infected or colonised 
patients is shown in Figure 3.
Discussion
The World Health Organization (WHO) has listed VRE 
as a pathogen with high priority in its global priority 
list of antibiotic-resistant bacteria [6]. While the inci-
dence of VRE varies between countries, the European 
mean vancomycin resistance prevalence was 11.8% 
in  E. faecium, in 2016 [7]. Transmission takes place 
via the environment (i.e., surfaces or medical devices) 
or healthcare workers and numerous outbreaks have 
been documented worldwide [8,9].
To the best of our knowledge, we report the first 
description of VRE ST796 clonal dissemination across 
several hospitals in Europe.  E. faecium  ST796 was 
first recognised at an Australian hospital during 2011 
[10] and spread rapidly throughout Australia and New 
Zealand hereafter. In 2013, it was identified as the 
cause of a large clonal outbreak of VRE in a neonatal 
unit of a hospital in Victoria [11]. In the following years, 
it spread from two Melbourne hospitals to hospitals in 
South Australia, New South Wales and New Zealand. 
VRE ST796 was shown to have largely replaced the pre-
viously predominant clone ST203 in a Melbourne hos-
pital, by 2014 [3]. The following year, ST796 was found 
to be responsible for 53% of all E. faecium VRE bacte-
raemias in Melbourne hospitals [5]. In 2015, a marked 
increase in VRE notifications occurred In Tasmania 
and, in 2016, ST796 had become the most important 
clone isolated at the major tertiary referral centre of 
this island [4]. Moreover, in 2016, ST796 was one of the 
most frequently detected VRE isolates among bacte-
raemic episodes in Australia [12]. ST796 E. faecium was 
described to cause colonisation with low rates of clini-
cal infection [11], however, a number of invasive VRE 
infections were also described in other hospitals [3].
The rapid inter-hospital spread across states and 
countries implies an effective transmission ability of 
this clone [3] and it does not appear that emerging 
healthcare-associated strains of E. faecium depend on 
enhanced antibiotic resistance for their success [3]. The 
complete genome of a representative E. faecium isolate 
ST796 (Ef_Aus0233) was examined and used to 
describe the evolution from an ST555 to ST796  E. 
faecium  isolate by means of several genomic events. 
This indicates the high propensity of the hospital  E. 
faecium  lineage to change, presumably in response 
to specific hospital environments [5]. An Australian 
group investigating hospital  E. faecium  isolates found 
increased tolerance to alcohol in isolates provided 
from 2010 onwards as compared with older isolates. 
They observed a positive association between time and 
increasing alcohol use, suggesting a high propensity of 
the bacteria to adapt under selective pressure – in this 
case possibly triggered by the use of alcohol based 
wipes [13].
The WGS analyses revealed a clear genomic relation-
ship between isolates from the outbreak in the Canton 
of Bern described here and those from Australia. The 
rapid spread of this multidrug-resistant clone may 
seriously endanger healthcare facilities and warrants 
strengthening and synchronisation of national infec-
tion control practices. In Switzerland, VRE incidence 
is not systematically monitored and national sur-
veillance data are lacking. In collaboration with the 
National Center of Infection Control (Swissnoso), and 
the Swiss Centre for Antibiotic Resistance (ANRESIS) a 
national programme on VRE epidemiology and the cor-
responding outbreak management has been launched 
in Switzerland on 29 June 2018.
Figure 3
Epidemic curve of vancomycin-resistant enterococci 
(VRE) cases by sequence type, Canton of Bern outbreak, 
Switzerland, December 2017–April 2018 (n = 89)
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*Authors’ correction 
In Figure 2, in the figure note, outbreak strains were mistak-
enly labelled as ‘red’. This was changed to ‘dark blue’ on 20 
July 2018 as requested by the authors.
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